Zymeworks is a biotechnology company engineering next-generation antibody-based therapies, particularly bispecific antibodies and antibody-drug conjugates. Its platforms enhance drug efficacy and safety for cancer treatment. Biopharma partners and patients benefit from improved therapeutic options. Zymeworks’ technology is licensed globally to develop targeted immunotherapies, advancing precision medicine.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends